An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
Crinetics Pharmaceuticals Inc.
Study ID
NCT06712823
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Classic Congenital Adrenal Hyperplasia
  • Congenital Adrenal Hyperplasia

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • atumelnant (CRN04894) — DRUG
    Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.

Study Details

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Key Dates

Start date
Feb 25, 2025
Status verified
Jun 2025
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Open-label treatment period (up to 2 years). The maximum atumelnant dose permitted is not to exceed the highest atumelnant dose explored in a parent study for the indication.

Primary Outcome Measure

Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation [ Time Frame: Week 108 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Crinetics Study Site, Minneapolis, Minnesota 55454MinneapolisMinnesota55455-
Crinetics Study SiteMorehead CityNorth Carolina28557-

Find similar trials in Minneapolis, MN

By research site
Crinetics Study Site, Minneapolis, Minnesota 55454· Minneapolis, MNCrinetics Study Site· Morehead City, NC

Related Studies